Figure 1.
The comparative serum proteome analysis of breast cancer patients with different risk of recurrence.
Serum proteome datasets of breast cancer patients with a lower risk of recurrence (LN-ER/PR+Her2-, n=50) or patients with a higher risk of recurrence (LN+ER/PR-Her2+, n=50) were obtained by using three different fractionation techniques (i.e. in-gel, 2DLC, or mRP) coupled with HPLC-CHIP-MS/MS. According to the criterion of differential protein as spectra counts ratio of LN-ER/PR+Her2- and LN+ER/PR-Her2+ datasets ≥10 or ≤0.1, the 70 significantly over-expressed proteins in LN-ER/PR+Her2- status were obtained. Following GO analysis, those 70 differential proteins were showed significantly over-represented in terms “response to biotic stimulus”, “response to endogenous stimulus”, “response to external stimulus”, “response to stimulus”, and “response to stress” (p<0.0001).
Figure 2.
Determination of serum sCD14 concentrations in patients of LN-ER/PR+Her2- and LN+ER/PR- Her2+ phenotype breast cancer by ELISA.
A significantly higher level of serum sCD14 was observed in patients with LN-ER/PR+Her2- status (n=93) than in that with LN+ER/PR-Her2+ status (n=90) (p<0.0001).
Figure 3.
Pre-validation of serum sCD14 as a biomarker for predicting the recurrence of breast invasive ductal carcinoma with LN+ER/PR-Her2+.
(A) Comparison of the level of serum sCD14 in relapse and relapse-free patients of breast cancer with LN+ER/PR-Her2+ status. The level of serum sCD14 was significantly lower in the patients with recurrence than those without recurrence (p<0.001). (B) The receiver operating characteristics (ROC) curve of serum sCD14. The AUC was 0.833 (95% CI, 0.742 to 0.920).
Figure 4.
Comparison of serum sCD14 levels between the recurrent patients of breast cancer with LN-ER/PR+Her2- status and those with LN+ER/PR-Her2+ phenotype.
The level of serum sCD14 was significantly higher in LN-ER/PR+Her2- status relapse patients than in LN+ER/PR-Her2+ status relapse patients (p<0.001).